Attachment characteristics and involvement of integrins in adhesion of breast cancer cell lines to extracellular bone matrix components

Laboratory Investigation

Volumn 77, Issue 6, 1997, Pages 665-675

  Van Der Pluijm, Gabri ^a   Vloedgraven, Hans ^a   Papapoulos, Socrates ^a   Löwik, Clemens ^a   Grzesik, Wojtek ^b   Kerr, Janet ^c   Robey, Pamela Gehron ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^c Department of Endocrinology C4 89 ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ARGINYLGLYCYLASPARTIC ACID; FIBRONECTIN; INTEGRIN; MEMBRANE RECEPTOR; OSTEOPONTIN; THROMBOSPONDIN; VITRONECTIN;

ARTICLE; BONE MATRIX; BONE METASTASIS; BREAST CANCER; CANCER CELL CULTURE; CELL ADHESION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BONE AND BONES; BREAST NEOPLASMS; CELL ADHESION; EXTRACELLULAR MATRIX; FEMALE; HUMANS; INTEGRINS; TUMOR CELLS, CULTURED;

EID: 0031445986     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Akiyama SK, Yamada SS, Chen W-T, and Yamada KM (1989). Analysis of fibronectin receptor function with monoclonal antibodies: Roles in cell adhesion, migration, matrix assembly and skeletal organization. J Cell Biol 109:863-875.
2. Albelda SM (1993). Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest 68:4-17.
3. Bellahcène A, Kroll M, Liebens F, and Castronovo V (1996a). Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J Bone Miner Res 11:665-670.
4. Bellahcène A, Menard S, Bufalino R, Moreau L, and Castronovo V (1996b). Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int J Cancer 69:350-353.
5. Bellahcène A, Merville M, and Castronovo V (1994). Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. Cancer Res 54:2823-2826.
6. Bianco P, Fisher LW, Young MF, Termine JD, and Gehron Robey P (1991). Expression of bone sialoprotein (BSP) in developing human tissues. Calcif Tissue Int 49:421-426.
7. Brown DL, Phillips DR, Damsky CH, and Charo IF (1989). Synthesis and expression of fibroblast fibronectin receptor in human monocytes. J Clin Invest 84:366-370.
8. Cailleau R, Young R, Olivé M, and Reeves WJ (1974). Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 53:661-674.
9. Carter WG, Wayner EA, Bouchard TS, and Kaur P (1990). The role of integrins α2β1 and α3β1 in cell-cell and cell-substrate adhesion of human epidermal cells. J Cell Biol 110:1387-1404.
10. Coleman RE and Rubens RD (1987). The clinical course of bone metastases from breast cancer. Br J Cancer 55:61-66.
11. Davies J, Warwick J, Totty N, Philip R, Helfrich M, and Horton M (1989). The osteoclast functional antigen, implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor. J Cell Biol 109:1817-1826.
12. Elte JWF, Bijvoet OLM, Cleton FJ, van Oosterom AT, and Sleeboom HP (1986). Osteolytic metastases in breast carcinoma: Pathogenesis, morbidity and bisphosphonate treatment. Eur J Cancer Clin Oncol 22:493-500.
13. Fisher LW (1992). Structure/function studies of the sialoglycoproteins and proteoglycans of bone: It is still the early days. In: Slavkin H and Price P, editors: Chemistry and biology of mineralized tissues. Amsterdam: Elsevier Science Publishers, 177-186.
14. Fisher LW, Whitson SW, Avioli LV, and Termine JD (1983). Matrix sialoprotein of developing bone. J Biol Chem 258: 12723-12727.
15. Gehron Robey P (1989). The biochemistry of bone. Endocrinol Metab Clin North Am 18:859-902.
16. Gehron Robey P and Termine JD (1985). Human bone cells in vitro. Calcif Tissue Int 37:453-460.
17. Gehron-Robey P, Young MF, Fisher LW, and McClain TD (1989). Thrombospondin is an osteoblast-derived component of mineralized extracellular matrix. J Cell Biol 108:719-727.
18. Grzesik WJ and Gehron Robey P (1994). Bone matrix RGD glycoproteins: Immunolocalization and interaction with human primary osteoblastic bone cells in vitro. J Bone Miner Res 9:487-496.
19. Gui GP, Puddefoot JR, Vinson GP, Wells CA, and Carpenter R (1995). In vitro regulation of human breast cancer cell adhesion and invasion via integrin receptors to the extracellular matrix. Br J Surg 82:1192-1196.
20. Hemler ME (1990). VLA proteins in the integrin family: Structures, functions, and their role on leukocytes. Annu Rev Immunol 8:365-400.
21. Hemler ME, Sanchez-Madrid F, Flotte TJ, Krensky AM, Burakoff SJ, Bhan AK, Springer TA, and Stromiger JL (1984). Glycoproteins of 210,000 and 130,000 m.w. on activated T-cells: Cell distribution and antigenic relation to components on resting cells and T cell lines. J Immunol 132:3011-3018.
22. Horton MA, Lewis D, McNulty K, Pringle JAS, and Chambers TJ (1985). Monoclonal antibodies to osteoclastomas (giant-cell bone tumors), definition of osteoclast-specific antigens. Cancer Res 45:5663-5669.
23. Ingram RT, Clarke BL, Fisher LW, and Fitzpatrick LA (1993). Distribution of noncollagenous proteins in the matrix of adult bone: Evidence for anatomic and functional heterogeneity. J Bone Miner Res 8:1019-1029.
24. Juliano RL (1993). The role of β1 integrins in tumors. Semin Cancer Biol 4:277-283.
25. Kennel SJ, Foote LJ, and Lankfort PK (1981). Analysis of surface proteins of mouse lung carcinomas using monoclonal antibodies. Cancer Res 41:3465-3470.
26. Kitazawa S and Maeda S (1995). Development of skeletal metastases. Clin Orthop Relat Res 312:45-50.
27. Kleinman HK, McGarvey ML, Hassell JR, Star VL, Cannon FB, Laurie GW, and Martin GR (1986). Basement membrane complexes with biological activity. Biochemistry 25:312-318.
28. Koukoulis GK, Virtanen I, Korhonen M, Laitinen L, Quaranta V, and Gould VE (1991). Immunohistochemical localization of integrins in normal, hyperplastic, and neoplastic breast. Am J Pathol 139:787-799.
29. Liapis H, Flath A, and Kitazawa S (1996). Integrin alpha V beta 3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol 5:127-135.
30. Maemura M and Dickson RB (1994). Are cellular adhesion molecules involved in the metastasis of breast cancer? Breast Cancer Res Treat 32:239-260.
31. Matsuura N, Puzon-McLaughlin W, Irie A, Morikawa Y, Kakudo K, and Takada Y (1996). Induction of experimental bone metastasis in mice by transfection of integrin alpha 4 beta 1 into tumor cells. Am J Pathol 148:55-61.
32. Mintz KP, Grzesik WJ, Midura RJ, Gehron Robey P, Termine JD, and Fisher LW (1993). Purification and fragmentation of undenatured bone sialoprotein: Evidence for a cryptic, RGD-resistant cell attachment domain. J Bone Miner Res 8:985-995.
33. Natali PG, Nicotra MR, Botti C, Mottolese M, Bigotti A, and Segatto O (1992). Changes in expression of alpha 6/beta 4 integrin heterodimer in primary and metastatic breast cancer. Br J Cancer 66:318-322.
34. Oda K, Hori S, Itoh H, Osamura RY, Tokuda Y, Kubota M, and Tajima T (1992). Immunohistochemical study of transforming growth factor beta, fibronectin, and fibronectin receptor in invasive mammary carcinoma. Acta Pathol Jpn 42:645-650.
35. Oldberg A, Franzen A, and Heinegård D (1986). Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell binding sequence. Proc Natl Acad Sci U S A 83:8819-8823.
36. Oldberg A, Franzen A, and Heinegård D (1988). The primary structure of a cell binding sialoprotein. J Biol Chem 263: 19430-19432.
37. Orr FW, Kostenuik P, Sanchez-Sweatman OH, and Singh G (1993). Mechanisms involved in the metastasis of cancer to bone. Breast Cancer Res Treat 25:151-163.
38. Paterson AHG (1987). Bone metastases in breast cancer, prostate cancer and myeloma. Bone 8(Suppl 1):S17-S22.
39. Pierschbacher MD and Ruoslahti E (1984). Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 309:30-33.
40. Pignatelli M, Cardillo MR, Hanby A, and Stamp GW (1992). Integrins and their accesory adhesion molecules in mammary carcinomas: Loss of polarization in poorly differentiated tumors. Hum Pathol 23:1159-1166.
41. Preissner KT (1991). Structure and biological role of vitronectin. Ann Rev Cell Biol 7:275-310.
42. Reinholt FP, Hultenby K, Oldberg A, and Heinegård D (1990). Osteopontin: A possible anchor of osteoclasts to bone. Proc Natl Acad Sci U S A 87:4473-4475.
43. Rosol TJ and Capen CC (1992). Biology of disease: Mechanisms of cancer-induced hypercalcemia. Lab Invest 67:680-702.
44. Sager R, Anisowicz A, Neveu M, Liang P, and Sotiropoulou G (1993). Identification by differential display of alpha 6 integrin as a candidate tumor suppressor gene. FASEB J 7:964-970.
45. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, and Yoneda T (1995). Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55:3551-3557.
46. Termine JD (1993). Bone matrix proteins and the mineralization process. In: Favus MJ, editor: Primer on the metabolic bone diseases and disorders of mineral metabolism. 2nd ed. New York: Raven Press, 21-25.
47. van der Pluijm G, Vloedgraven HJM, Ivanov B, Robey FA, Grzesik WJ, Gehron Robey P, Papapoulos SE, and Löwik CWGM (1996a). Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone. Cancer Res 56:1948-1955.
48. van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals LJA, Löwik CWGM, and Papapoulos SE (1996b). Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98:698-705.
49. Varner JA and Cheresh DA (1996). Integrins and cancer. Curr Opin Cell Biol 8:724-730.
50. von Kossa J (1901). Ueber die im Organismus künstlich erzeugbaren Verkalkungen. Beitr Pathol Anat 29:163-202.
51. Wayner EA, Carter WG, Piotrowicz RS, and Kunicki TJ (1988). The function of multiple extracellular matrix receptors in mediating cell adhesion to extracellular matrix: Preparation of monoclonal antibodies to the fibronectin receptor that specifically inhibit cell adhesion to fibronectin and react with platelet glycoproteins Ic-IIa. J Cell Biol 107:1881-1891.
52. Wayner EA, Garcia-Pardo A, Humphries MJ, McDonald JA, and Carter WG (1989). Identification and characterization of T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin. J Cell Biol 109: 1321-1330.
53. Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, and Bissell MJ (1997). Reversion of the malignant phenotype of human breast cancer cells in three dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 137:231-245.
54. Weiss RE and Reddi AH (1981). Synthesis and localization of fibronectin during collagenous matrix-mesenchymal cell interaction and differentiation of cartilage and bone in vivo. Proc Natl Acad Sci U S A 77:2074-2078.
55. Werb Z, Tremble PM, Behrendtsen O, Crowley E, and Damsky C (1989). Signal transduction through the fibronectin receptor induces collegenase and stromelysin gene expression. J Cell Biol 109:877-889.
56. Yoneda T, Sasaki A, and Mundy GR (1994). Osteolytic bone disease in breast cancer. Breast Cancer Res Treat 32:73-84.
57. Zetter BR (1993). Adhesion molecules in tumor metastasis. Semin Cancer Biol 4:219-229.
58. Zutter MM, Mazoujian G, and Santoro SA (1990). Decreased expression of integrin adhesive protein receptors in adenocarcinoma of the breast. Am J Pathol 137:863-870.
59. Zylstra S, Chen FA, Ghosh SK, Repasky EA, Rao U, Takita H, and Bankert RB (1986). Membrane-associated glycoprotein (gp160) identified on human lung tumors by a monoclonal antibody. Cancer Res 46:6446-6451.